This page shows the latest Michael Ehlers news and features for those working in and with pharma, biotech and healthcare.
Follows multiple late-stage Alzheimer's study failures. Michael Ehlers. Biogen’s head of R&D Michael Ehlers (pictured above) is leaving the company after three years, and some high-profile ... Along with his CEO role at Limelight, Ehlers is also taking
tofersen in SOD1-ALS patients and further demonstrate the potential of ASOs to target the genetic driver of disease,” said Michael Ehlers, executive vice president, research and development at Biogen. ... Michael Ehlers recently said the company
We believe we have a path forward and we are working to lift the hold as quickly as possible,” said Biogen’s head of R&D Michael Ehlers on the call.
When cognition is impaired, you lose the ability to make sense of the world,” said Michael Ehlers, Biogen’s head of R&D.
On a conference call to discuss Biogen’s fourth quarter results, R&D head Michael Ehlers said that KPT-350 is a “first-in-class phase I ready investigational oral compound
enzyme. Pfizer’s decision comes after its former head of neuroscience R&D Michael Ehlers left to take up the top R&D role at Biogen in 2016.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...